Can a woman of child‑bearing age safely continue Strattera (atomoxetine) during pregnancy or when planning pregnancy, or should it be discontinued?

Strattera (Atomoxetine) and Pregnancy

Women taking Strattera (atomoxetine) for ADHD who are pregnant or planning pregnancy should engage in a thorough risk-benefit discussion with their physician, but can generally continue the medication if needed for daily functioning, as current evidence shows no increased risk of major congenital malformations or adverse long-term neurodevelopmental outcomes. 1

Evidence for Safety During Pregnancy

Congenital Malformations

• Atomoxetine does not appear to be associated with major congenital malformations, including cardiac malformations, though data remain limited 1
• A large, well-controlled study demonstrated no increased risks for neurodevelopmental psychiatric disorders, impairments in vision or hearing, epilepsy, seizures, or growth impairment in children exposed to atomoxetine during pregnancy 1
• Meta-analysis of 16.6 million pregnancies found no significant increase in congenital anomalies (OR 1.14,95% CI 0.83-1.55) with methylphenidate or atomoxetine exposure 2
• A multinational cohort study of 2.4 million Nordic pregnancies and 1.8 million US pregnancies found adjusted prevalence ratio of 0.99 (95% CI 0.74-1.34) for major congenital malformations after first-trimester atomoxetine exposure 3

Obstetrical Outcomes

• Possible increased risk for spontaneous abortion, but confounding by indication (ADHD itself) cannot be ruled out 1
• Meta-analysis showed no increased risk of miscarriages (OR 1.01,95% CI 0.70-1.47) 2
• No evidence of increased preeclampsia, preterm birth, or poor neonatal adaptation specifically with atomoxetine 1

Long-Term Neurodevelopmental Outcomes

• A 2025 Swedish population-based cohort study of 861,650 children found no increased risk for any neurodevelopmental disorder (HR 0.95% CI 0.82-1.11), ADHD (HR 0.92,95% CI 0.78-1.08), or autism spectrum disorder (HR 0.86,95% CI 0.63-1.18) with in utero atomoxetine exposure 4
• Meta-analysis combining Swedish and Danish data confirmed these findings (pooled HR 1.00,95% CI 0.83-1.20) 4

Clinical Decision-Making Algorithm

Preconception Planning

• If atomoxetine is not severely impacting daily functioning: Consider a trial of gradually discontinuing before pregnancy 1
• If medication is essential for functioning: Continue current medication, reduce to lowest effective dose, consider intermittent use, or discuss switching to a nonstimulant option 1
• Engage in comprehensive risk-benefit discussion regarding medication choice and dosing 1

During Pregnancy

• If atomoxetine is required for daily functioning, treatment should not be stopped as the magnitude of documented risks is very low 1
• Continue well-tolerated, effective dose or consider intermittent use through risk-benefit discussion 1
• Monitor pregnancy carefully: fetal growth, blood pressure checks, appropriate maternal weight gain 1

Alternative Considerations

• Switching to bupropion may be considered, particularly for individuals with co-occurring depression, given available safety data, though bupropion is less efficacious than stimulants for ADHD 1
• Non-pharmacologic treatments (psychoeducation, cognitive behavioral therapy, mindfulness-based interventions) may be attempted for mild-to-moderate ADHD 1

Breastfeeding Considerations

Current Evidence

• Caution is advised as there are no published studies of atomoxetine during breastfeeding 1
• Based on pharmacokinetics (low molecular weight, long half-life), atomoxetine will likely be present in human milk 1
• NEW DATA (2026): A human milk biorepository study found mean atomoxetine concentration of 12 ng/mL with relative infant dose (RID) of only 0.19%, well below the 5% safety threshold for psychoactive medications 5
• No adverse effects were reported in breastfed infants in this study 5
• Worst-case scenario RID was calculated at 0.65%, still considered safe 5

Breastfeeding Recommendations

• Atomoxetine appears to be a suitable choice for ADHD management in lactating women based on minimal transfer into breast milk 5
• Monitor infant development carefully: ensure appropriate weight gain and developmental milestones 1
• Consider timing of feeding or pumping to achieve lowest concentration in milk if concerned 1

Important Caveats

FDA Labeling

• The FDA label states that pregnant or nursing women should not use Strattera unless potential benefit justifies potential risk to fetus or infant 6
• Patients should be instructed to consult a physician if nursing, pregnant, or thinking of becoming pregnant while taking Strattera 6

Clinical Context

• ADHD itself may pose risks during pregnancy including exacerbation of symptoms that can impact maternal functioning and pregnancy management 1
• The consensus from 2024 American Journal of Obstetrics and Gynecology guidelines is that documented medication risks are very low and treatment should not be stopped if required for daily functioning 1
• Evidence suggests risks may be elevated in ADHD in general rather than being directly attributable to medication 1

Monitoring Requirements

• Watch for severe liver injury signs: pruritus, dark urine, jaundice, right upper quadrant tenderness, unexplained flu-like symptoms 6
• Monitor for psychiatric symptoms: anxiety, agitation, hostility, depression, suicidal ideation, especially early in treatment 6
• Cardiovascular monitoring: blood pressure and heart rate throughout pregnancy 6